Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of “Buy” by Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received an average rating of “Buy” from the six analysts that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $30.50.

A number of research firms recently weighed in on CPRX. Truist Financial boosted their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Citigroup boosted their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th.

Catalyst Pharmaceuticals Trading Down 2.0 %

Shares of NASDAQ CPRX opened at $23.45 on Tuesday. The stock’s 50-day moving average is $20.81 and its 200 day moving average is $18.17. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 19.87, a P/E/G ratio of 3.82 and a beta of 0.75. Catalyst Pharmaceuticals has a 1-year low of $12.43 and a 1-year high of $24.27.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares in the company, valued at $13,738,773.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Oppenheimer & Co. Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the first quarter valued at approximately $805,000. Sei Investments Co. grew its stake in Catalyst Pharmaceuticals by 64.3% in the first quarter. Sei Investments Co. now owns 83,360 shares of the biopharmaceutical company’s stock worth $1,329,000 after purchasing an additional 32,621 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in Catalyst Pharmaceuticals in the second quarter worth $258,000. Integral Health Asset Management LLC purchased a new stake in Catalyst Pharmaceuticals in the second quarter worth $4,260,000. Finally, Vanguard Group Inc. grew its stake in Catalyst Pharmaceuticals by 12.1% in the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after purchasing an additional 860,244 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.